Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493649 · ClinicalTrials.gov registry record · Phase 2
Adj TC + Herceptin Early Stage Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 493
- Enrollment target
- 20
- Study locations
NCT00493649: Completed Phase 2 study of Breast Cancer, sponsored by US Oncology Research.
NCT00493649 is a Phase 2 study of Breast Cancer that has completed, run by US Oncology Research. The registered enrollment target is 493 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493649, a Phase 2 study of Breast Cancer, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 493 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.
Conditions Studied
Interventions
- DRUG Taxotere
- DRUG Cytoxan
- DRUG Herceptin
Study Locations (20)
Arizona
- Hematology Oncology Associates - Phoenix
- Northern AZ Hematology & Oncology Associates - Sedona
- Arizona Oncology Associates DBA HOPE - Tucson
Florida
- Florida Cancer Institute - New Port Richey
- Ocala Oncology Center - Ocala
- Cancer Centers of Florida, P.A. - Ocoee
Illinois
- Hematology Oncology Associates of IL - Chicago
- Cancer Care & Hematology Specialists of Chicagoland - Niles
Indiana
- Central Indiana Cancer Centers - Indianapolis
- Hope Center - Terre Haute
Maryland
- Maryland Oncology Hematology, P.A. - Columbia
- Alliance Hematology Oncology P.A. - Westminster
Missouri
- Missouri Cancer Associates - Columbia
- Arch Medical Services, Inc. - St Louis
Alabama
- Birmingham Hematology and Oncology - Birmingham
Colorado
- Rocky Mountain Cancer Center-Rose - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 493 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493649
The ClinicalTrials.gov registry entry for NCT00493649 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 493 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower). The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Taxotere is the first listed.
NCT00493649 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Arizona, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00493649 about?
NCT00493649 is a clinical study titled "Adj TC + Herceptin Early Stage Breast Cancer". The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.
What is the current status of trial NCT00493649?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 493 participants. The study started on 2007-06. Estimated completion is 2013-04.
What conditions does trial NCT00493649 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00493649?
The interventions under investigation include: Taxotere (DRUG), Cytoxan (DRUG), Herceptin (DRUG).
Who is sponsoring clinical trial NCT00493649?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00493649 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.